Numerical scoring for the BILAG-2004 index-Reference-Cited by-同舟云学术

Numerical scoring for the BILAG-2004 index

Published:2010-02-24 Issue:9 Volume:49 Page:1665-1669
ISSN:1462-0332
Container-title:Rheumatology
language:en
Short-container-title:

Author:

Yee Chee-Seng,Cresswell Lynne,Farewell Vernon,Rahman Anisur,Teh Lee-Suan,Griffiths Bridget,Bruce Ian N.,Ahmad Yasmeen,Prabu Athiveeraramapandian,Akil Mohammed,McHugh Neil,D’Cruz David,Khamashta Munther A.,Isenberg David A.,Gordon Caroline

Publisher

Oxford University Press (OUP)

Subject

Pharmacology (medical),Rheumatology

Link

http://academic.oup.com/rheumatology/article-pdf/49/9/1665/17387058/keq026.pdf

Reference9 articles.

1. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupuserythematosus;Isenberg;Rheumatology,2005

2. Revised British Isles Lupus Assessment Group 2004 index: a reliable tool for assessment of systemic lupus erythematosus activity;Yee;Arthritis Rheum,2006

3. British Isles Lupus Assessment Group 2004 index is valid for assessment of disease activity in systemic lupus erythematosus;Yee;Arthritis Rheum,2007

4. The BILAG-2004 index is sensitive to change for assessment of SLE disease activity;Yee;Rheumatology,2009

5. Numerical scoring for the Classic BILAG index;Cresswell;Rheumatology,2009

Cited by 113 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical markers, metrics, indices, and clinical trials;Dubois' Lupus Erythematosus and Related Syndromes;2025

2. Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics;Immunity;2024-09

3. Immunogenicity, reactogenicity, and safety of two-dose adjuvanted herpes zoster subunit vaccine in patients with systemic lupus erythematosus in South Korea: a single-centre, randomised, double-blind, placebo-controlled trial;The Lancet Rheumatology;2024-06

4. Type I interferon associated epistasis may contribute to early disease-onset and high disease activity in juvenile-onset lupus;Clinical Immunology;2024-05

5. Clinical trial outcomes for SLE: what we have and what we need;Lupus Science & Medicine;2024-02